Atrial natriuretic peptide, copeptin and adrenomedullin levels in polycystic ovary syndrome: a case-control study. (2nd January 2017)

• Record Type: Journal Article
• Authors: Frøssing, Signe; Nylander, Malin; Aziz, Mubeena; Skouby, Sven O.; Kistorp, Caroline; Faber, Jens
• Is Part Of: Gynecological endocrinology. Volume 33:Number 1(2017)
• Page Start: 30
• Page End: 33
• Publication Date: 2017-01-02
• Subjects: Adrenomedullin -- atrial natriuretic peptide -- cardiovascular -- copeptin -- insulin resistance -- polycystic ovary syndrome; Endocrine gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; 618.1
• DOI: 10.1080/09513590.2016.1202915
• Languages: English
• ISSNs: 0951-3590

Abstract

Abstract: Background : Polycystic ovary syndrome (PCOS) defined by the Rotterdam criteria does not take into account the unhealthy metabolic profile of the syndrome with increased insulin resistance (IR) and overweight favoring development of type 2 diabetes, hypertension and cardiovascular disease (CVD). We assess three vasoactive peptides associated with CVD in women with PCOS. Method : Plasma levels of mid-regional pro-atrial natriuretic peptide (MR-proANP), copeptin and mid-regional pro-adrenomedullin (MR-proADM) were measured in 98 PCOS patients and 46 age- and BMI-matched healthy women. Results : We found no difference in levels of MR-proANP, copeptin and MR-proADM between the PCOS and control group. Multiple regression analyses on a combined group of PCOS and control subjects demonstrated an inverse correlation between MR-proANP and IR (measured by fasting C-peptide) and a positive correlations between copeptin and IR as well as MR-proADM and BMI. We found no association between peptide levels and different Rotterdam phenotypes. Conclusion : Plasma concentrations of MR-proANP, copeptin and MR-proADM were not increased in PCOS compared to age- and BMI-matched controls. Thus, these peptides cannot be used to detect increased risk of CVD in a young PCOS cohort.